ArticleResearch square2024

IRF2 loss is associated with reduced MHC I pathway transcripts in subsets of most human cancers and causes resistance to checkpoint immunotherapy in human and mouse melanomas.

Gulce Sari et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.